With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Additionally, the company’s commercial strategy to ensure broad access, including discussions with Integrated Delivery Networks (IDNs) and payers, positions Vertex favorably in the market ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The primary outcome measured was the low-risk cesarean delivery rate, specifically the nulliparous, term, singleton, vertex cesarean delivery rate. The study found that FM-only hospitals ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle ...

Trinasolar has recently reached a significant milestone, delivering more than 1 GW of its Vertex N 720W series modules to the ...

CREC will receive delivery of Trinasolar’s Vertex N 720W Series of n-type tunnel oxide passivated contact (TOPCon) modules.

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and raises full-year guidance, while navigating challenges ...

At the heart of SurgeGraph Vertex is the Humanizer, a technology that automatically refines and delivers AI-generated content ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...